UiPath Stock Rises 44% in 6 Months: Should You Buy, Hold or Sell?

                                                        Image Source: Zacks Investment Research

PATH’s Agentic AI Adoption Continues to Accelerate

One of the most encouraging developments for UiPath is the growing adoption of its agentic AI platform. Roughly a year after making its agentic products generally available, the company is seeing customers progress from pilot programs to full-scale production deployments.

This transition is significant because production deployments indicate that customers are beginning to derive measurable value from the technology and incorporate AI capabilities into mission-critical workflows, rather than merely experimenting with them.

UiPath’s role also extends beyond supplying individual AI agents. Its platform functions as an orchestration layer that coordinates workflows, automates execution and integrates AI-generated outputs directly into enterprise operations. As organizations deploy more AI agents, the need to manage and govern increasingly complex workflows could make this orchestration capability more valuable.

The recent introduction of UiPath for Coding Agents further strengthens the company’s AI strategy. By helping customers accelerate deployments and shorten time to value, the offering could encourage broader adoption of UiPath’s platform across enterprise accounts.

Maestro Case Expands PATH’s Enterprise Platform

UiPath recently broadened its automation portfolio with the launch of Maestro Case, a capability designed to manage complex, long-running workflows involving multiple participants, business systems and AI agents.

Many organizations still depend on fragmented combinations of emails, spreadsheets and disconnected applications to handle customer requests, approvals and investigations. Maestro Case seeks to address these inefficiencies by treating each business case as a dynamic workflow that combines automation with human judgment and oversight.

UiPath’s growing enterprise presence also strengthens its position relative to Pegasystems PEGA, ServiceNow NOW and Salesforce CRM. While ServiceNow has built a strong franchise in enterprise workflow management and Pegasystems has long specialized in case management and business process automation, UiPath aims to differentiate itself by integrating robotic process automation, workflow orchestration and agentic AI within a unified platform. As enterprises increasingly seek AI-enabled workflow solutions, PATH's broader automation capabilities could provide a meaningful competitive advantage over Pegasystems and ServiceNow.

Large-Customer Growth Supports the Long-Term Outlook

UiPath continues to demonstrate solid enterprise adoption, particularly among its largest customers.

The number of customers generating more than $100,000 in annual recurring revenue increased to 2,624 from 2,365 over the past year, reflecting broader platform adoption and continued expansion within existing enterprise accounts.

More notably, customers contributing more than $1 million in ARR rose to 374 from 316. These large accounts typically represent deeper platform deployments, stronger retention and greater opportunities for long-term expansion.

Slowing Growth Could Limit Further Upside for PATH

UiPath’s consensus outlook indicates continued growth, but the expected trajectory remains less convincing. Current-quarter revenues are projected to increase 9.9% year over year to $397.6 million, followed by a slowdown to 7.3% growth in the subsequent quarter. Although full-year revenue growth is forecast at 10.4%, the rate is expected to moderate to 8.2% next year, pointing to weakening momentum.

Current-quarter earnings are projected to remain flat at 25 cents per share, underscoring limited near-term operating leverage. The relatively wide range of forward EPS estimates also highlights uncertainty surrounding the pace and consistency of profitability improvements.

                                                                        Image Source: Zacks Investment Research

UiPath’s accelerating agentic AI adoption, expanding product portfolio and growing base of large enterprise customers support its long-term prospects. Nevertheless, slowing revenue growth, stagnant near-term earnings and continued execution risk could limit additional upside following the stock’s strong rally. Investors may therefore want to wait for clearer evidence of sustained growth and improving operating leverage before becoming more constructive on PATH.

PATH Merits a Hold for Now

UiPath’s expanding agentic AI capabilities, broader automation portfolio and deeper enterprise adoption provide a solid foundation for long-term growth. Its ability to combine robotic process automation, workflow orchestration and AI agents could strengthen its relevance as businesses modernize complex operations. However, intensifying competition, cautious technology spending and uncertain execution remain notable risks. More importantly, moderating revenue growth and limited near-term earnings momentum may constrain further share-price appreciation following the recent rally. The company’s strategic progress supports retaining existing positions, but the current risk-reward balance does not present a compelling entry point. Investors should therefore consider UiPath a Hold for now.

PATH stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research